Smart Working: dealing with IT support implications

Smart Working: dealing with IT support implications by Dario Palese Current global health emergency situation is forcing the most of companies to maximize the smart working solution: In order to ensure the same performance whether working in the office or in smart working, IT services need to face this new reality. This means to refocus […]

PQE opens new offices in India Poland Usa and Belgium

PQE opens new offices in USA, India, Poland and Belgium

New offices opened in Boston (MA, USA), Chandigarh (India), Gdansk (Poland) and Mons (Belgium). PQE Group expands its borders by embracing new countries in Europe such as Belgium and Poland and increasing its presence in the United States and India.

PQE Group Smart Pharmaceutical Manufacturing SPUMONI Coalition - Fareva - University Thessaly - Politechnic Valencia - National College Ireland - EU presidency CHIST-ERA Smart Industry

PQE leads the Smart Pharmaceutical Manufacturing coalition (SPuMoNI)

A call for Smart Industry by CHIST-ERA on Big Data and Process Modelling A programme for European Coordinated Research on Long-term Information and Communication Technologies (ICT) and ICT-based scientific challenges, CHIST-ERA annually calls for research proposals on key emerging topics. In 2017, the brief was ‘Big Data and process modelling for smart industry’. Partnering with […]

Cybersecurity for Medical Devices risks and vulnerabilities

Why MD Cybersecurity is so important

Why MD Cybersecurity is so important? PQE Group – 3/12/2019 The hidden risks of a disruptive innovation. Is Cybersecurity important for Medical Devices? The answer is absolutely yes. But let’s move a bit backwards, to understand the reason why nowadays Cybersecurity has become a main concern for all Medical Devices producers. It’s well renowned that […]

Nitrosamines impurities risk evaluation

CMDh raising risk awareness on Nitrosamine Impurities

On September 26th, 2019 the CMDh published the notice “Information on nitrosamines for marketing authorisation holders” asking to all Marketing Authorization Holders (MAHs) of human medicinal products containing chemically synthesised active pharmaceutical ingredients to evaluate the risk of the presence of nitrosamine impurities in their products. This includes generics and over-the counter (OTC) products.

OsservatorioPMI 2019. PQE Group receives the “Excellent Company” award

PQE Group has been awarded for the 2nd year in a row, starring in ESG evaluation and business growth. Borsa Italiana (MI), Sept. 25th, 2019 – PQE Group received the Excellent Companies’ Award for 2019. For the company based in Reggello (Florence, Italy), and led by the founder and C.E.O. Gilda D’Incerti, this is the […]

“Ciao Pino!” PQE funds ALS Research in memory of deceased client employee.

In memory of beloved Giuseppe “Pino” Santoni, member of Pfizer company, his colleagues created a web page to donate for a good cause, funding research on ALS. You can find the web page here . Also PQE joined the call with the highest feelings, both for sustaining ALS research and in memory of Pino, contributing […]